For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
AOD-9604 is a synthetic 16-amino acid fragment of the C-terminus of human growth hormone (hGH residues 176 to 191), developed at Monash University in the 1990s as a selective anti-obesity drug. Six human clinical trials involving approximately 900 participants established a clean safety profile. A Phase IIa trial (n=300, 12 weeks) showed 2.6 to 2.8 kg additional weight loss at 1 mg/day versus 0.8 kg placebo. The pivotal Phase IIb OPTIONS trial (n=536, 24 weeks) failed to replicate this finding at any dose. Development was terminated in 2007. Cannot be legally compounded in the United States as of March 2026.
AOD-9604's clinical history is the single most important thing to understand about it, and vendors reliably omit the critical half: the drug failed its pivotal trial. The positive Phase IIa data (2.6 to 2.8 kg additional weight loss over 12 weeks, n=300) is real, but it is followed by the OPTIONS Phase IIb study (n=536, 24 weeks) which found no statistically significant weight loss at any dose. Development was terminated in 2007. AOD-9604 has never been approved by the FDA, TGA (Australia), EMA, or any regulatory authority worldwide as a drug.
The regulatory status as of March 2026 is unambiguous: AOD-9604 cannot be legally compounded in the United States. The FDA placed it on the Category 2 interim bulks list in September 2023 (banned from compounding). It was removed from Category 2 in September 2024 when the nominator withdrew. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed it at the December 4, 2024 meeting and voted against recommending inclusion on the 503A bulks list. As of March 2026, AOD-9604 does not meet the criteria for legal compounding and is sold only as an unregulated research chemical.
The GRAS (Generally Recognized as Safe) status claimed in marketing materials applies to food and dietary supplement oral use only. It does not constitute drug approval, does not cover injectable use, and does not override FDA's compounding restrictions.
AOD-9604 was developed by Professor Frank Ng at Monash University in Melbourne, Australia, in the 1990s, starting from the observation that human growth hormone (hGH) has potent lipolytic effects in obese animal models, but full-length hGH also causes insulin resistance, IGF-1 elevation, and growth promotion, effects that preclude its use as an anti-obesity drug.
Ng's group identified the C-terminal region of hGH (residues 177 to 191) as the fragment responsible for fat metabolism effects, distinct from the N-terminal regions responsible for growth and IGF-1 stimulation. A modified version with an added tyrosine at the N-terminus (creating a 16-amino acid peptide, residues 176 to 191) was synthesized and named AOD-9604. The tyrosine modification stabilized the peptide and improved oral bioavailability.
Metabolic Pharmaceuticals Ltd. in Melbourne took AOD-9604 through clinical development, funding partly by Australian Commonwealth Government grants, through six human clinical trials including two Phase IIb studies. Development was terminated in 2007 following the Phase IIb failure.
AOD-9604's mechanism has not been fully characterized despite decades of research, which is itself a meaningful scientific limitation.
The primary proposed mechanism is activation of beta-3 adrenergic receptors (beta-3-AR) in adipose tissue. In obese animal models, beta-3-AR gene expression is suppressed; AOD-9604 has been shown to partially restore beta-3-AR RNA levels in obese mice toward those seen in lean mice. Beta-3-AR activation stimulates lipolysis via cyclic AMP-dependent upregulation of hormone-sensitive lipase, cleaving stored triglycerides into free fatty acids and glycerol for oxidation. This was confirmed mechanistically in beta-3-AR knock-out mice, where AOD-9604 lost its lipolytic effect (Heffernan 2001).
A parallel mechanism involves inhibition of lipogenesis, meaning the conversion of non-fatty substrates into stored fat. Both lipolysis activation and lipogenesis inhibition are documented in rodent models and are consistent with the observed fat-selective effects.
AOD-9604 does not bind the GH receptor with high affinity and does not stimulate IGF-1 production in any system studied. This cleanly distinguishes it from full-length hGH and explains the absence of growth-promoting and insulin-destabilizing effects at all tested doses.
The mechanism does not involve central nervous system appetite modulation. AOD-9604 does not cross the blood-brain barrier and does not affect hypothalamic hunger circuits. The absence of appetite suppression is both a safety advantage and a likely contributor to the modest and ultimately non-replicating clinical weight loss outcomes: fat mobilization alone, without the appetite reduction that GLP-1 agents produce, generates smaller net energy deficits.
Phase IIa (Wittert 2004, n=300, 12 weeks): The 1 mg/day dose group lost an average of 2.6 to 2.8 kg versus 0.8 kg in the placebo group, a statistically significant difference. A small but consistent improvement in cholesterol profiles and reduction in the proportion of patients with impaired glucose tolerance were also observed. The dose-response relationship was not monotonic: the 1 mg dose outperformed all higher doses (5, 10, 20, 30 mg), a finding that was not adequately explained mechanistically.
Phase IIb OPTIONS trial (n=536, 24 weeks, doses 0.25, 0.5, 1 mg/day): The primary endpoint, weight loss at 12 weeks at any dose versus placebo, was not met. No statistically significant weight loss was detected at any dose. This was not a marginal miss: the pivotal study, designed with adequate power to confirm the Phase IIa signal, failed to do so. Metabolic Pharmaceuticals terminated development in 2007. One contributing factor cited in the literature was the incorporation of an intensive diet and exercise program in Phase IIb that may have reduced the drug-placebo difference.
AOD-9604's weight loss record is a textbook example of Phase IIa replication failure. The 12-week signal in 300 patients did not survive a 536-patient 24-week replication attempt. Most biohacker and vendor content cites only the Phase IIa result. The Phase IIb failure is the dominant clinical fact. The compound remains unvalidated for obesity treatment.
In vitro studies using bovine chondrocytes showed that AOD-9604 promotes proteoglycan and collagen synthesis, suggesting potential utility in cartilage repair or osteoarthritis. Adipose-derived mesenchymal stem cell studies demonstrated that AOD-9604 promotes differentiation toward osteogenic (bone-forming) phenotypes, raising a hypothesis for bone repair applications.
No animal osteoarthritis model trial and no human trial in any musculoskeletal indication have been published. Metabolic Pharmaceuticals announced plans for an osteoporosis Phase 2 trial in 2007, but no results appear in the indexed literature following the weight loss program's termination.
The cartilage repair hypothesis is frequently cited as an emerging application but is supported only by in vitro bovine cell data. There is no animal osteoarthritis model, no primate study, and no human trial. The gap between bovine chondrocyte in vitro findings and clinical utility in human joint disease is large. Early preclinical at best.
Across all six human clinical trials (approximately 900 participants), AOD-9604 had no effect on serum IGF-1 levels at any dose. No effects on fasting glucose or insulin sensitivity were detected. This contrasts with full-length hGH, which reliably raises IGF-1 and impairs glucose tolerance.
In beta-3-AR knock-out mice, AOD-9604 lost its lipolytic effect entirely, confirming the beta-3-AR-dependent mechanism and demonstrating that the fat-reduction pathway is not mediated through the GH receptor or IGF-1 axis.
The dissociation of fat-metabolic effects from IGF-1 and glucose disruption is the most consistently replicated and credible finding in the AOD-9604 literature, supported across all six human trials. For individuals seeking fat mobilization without IGF-1 elevation, this pharmacological profile is theoretically attractive. The limitation is that the fat-metabolic effect itself failed in Phase IIb, so this advantage exists in the context of an unproven primary benefit.
Regulatory timeline in the United States: September 2023: FDA added AOD-9604 to Category 2 of the interim 503A bulks list, citing significant safety concerns including theoretical immunogenicity risk from compounding impurities. Category 2 prohibits compounding. September 2024: Nominator withdrew AOD-9604 from the nomination list, removing it from Category 2, but compounding remained impermissible as AOD-9604 meets none of the three criteria for 503A compounding: it is not a component of an FDA-approved drug, has no USP/NF monograph, and was not on the FDA bulks list. December 4, 2024: PCAC voted against recommending inclusion on the 503A bulks list. FDA staff cited immunogenicity concerns and inadequate characterization data for compounded preparations. Eli Lilly publicly opposed inclusion during the open comment session. PCAC votes are advisory; formal rulemaking is still required to finalize.
GRAS status: Conditionally granted for food and dietary supplement oral use at specified concentrations. Applies to oral, non-drug contexts only. Does not constitute drug approval. Does not cover injectable use. Does not override compounding restrictions.
The regulatory situation has been volatile and is routinely misrepresented. GRAS status does not mean injectable safety approval. The PCAC vote against 503A inclusion signals FDA intent to continue prohibiting compounding. Anyone receiving AOD-9604 as a compounded injectable in the United States in 2026 is likely receiving it from a non-compliant facility. This is a critical disclosure for any research or clinical context.
GH fragment with lipolytic activity. Phase 2 showed modest fat loss; program discontinued 2007.
All human efficacy and safety data are for oral administration. Biohacker protocols use subcutaneous injection at 250 to 500 mcg/day, a route and dose combination not studied in any human clinical trial. Oral bioavailability is estimated at 5 to 15%, meaning subcutaneous doses may produce higher systemic exposures than the oral doses that generated the Phase IIa signal. No human PK study for subcutaneous AOD-9604 has been published. The compound cannot be legally compounded in the United States as of March 2026.
Among weight loss peptides in this series, AOD-9604 has more human trial data than any other purely peptide-based fat loss compound, but sits well below the GLP-1 agonists (Semaglutide, Tirzepatide, Retatrutide) in every meaningful comparison. GLP-1 agents have Phase 3 approval and produce 15 to 22% weight loss in pivotal trials. AOD-9604 has a failed Phase 2b and approximately 2 kg of additional loss in a non-replicated 12-week trial. The mechanism (peripheral fat mobilization, no appetite modulation) is distinct from GLP-1 action and is not directly competitive. For body composition without IGF-1 effects, it occupies a different theoretical niche than full-length hGH or IGF-1 LR3.
Across approximately 900 participants in six human clinical trials, no serious adverse events were attributed to AOD-9604. No anti-drug antibodies (immunogenicity) were detected in any study. No effects on IGF-1, fasting glucose, or insulin sensitivity were observed. Adverse event rates were not meaningfully different from placebo.
Animal toxicology is comprehensive. The no-observed-adverse-effect level (NOAEL) in chronic rat studies is at least 100 mg/kg/day. In cynomolgus monkeys, chronic dose levels up to 50 mg/kg/day were considered NOAEL. No genotoxicity, carcinogenicity, or reproductive toxicity was identified in standard preclinical battery testing.
An FDA FAERS database search through January 2024 found zero adverse event reports for AOD-9604. A search of CAERS (consumer adverse event database) from 2004 to 2024 also found no cases.
The FDA's stated concerns at the December 4, 2024 PCAC meeting centered on theoretical immunogenicity risk from impurities in compounded preparations, not demonstrated harm from the molecule itself. The concern is about compounding quality control, not the intrinsic safety of AOD-9604 as characterized in clinical trials.
The uncharacterized risk is subcutaneous injection at biohacker doses (250 to 500 mcg/day). Given oral bioavailability estimates of 5 to 15%, subcutaneous doses in this range may produce higher systemic exposures than the 0.25 to 1 mg/day oral doses used in clinical trials. No human PK study for subcutaneous AOD-9604 exists.
AOD-9604 is a case study in the gap between Phase IIa promise and Phase IIb reality. The Phase IIa signal (2.6 to 2.8 kg additional weight loss in 300 patients) was genuinely encouraging and represented the best human data for any weight loss peptide at the time. The OPTIONS Phase IIb (n=536, 24 weeks) did not replicate it. No weight loss pharmaceutical program survives a failed pivotal study, and Metabolic Pharmaceuticals terminated development in 2007.
The safety record across approximately 900 human participants is clean and thoroughly documented. The pharmacological profile (lipolysis without IGF-1, without glucose disruption, without central appetite effects) is scientifically interesting. The cartilage and bone repair hypothesis is biologically plausible but lacks any in vivo human or animal osteoarthritis model data.
The practical reality in 2026: AOD-9604 is sold through research chemical vendors, cannot be legally compounded in the United States, and has a failed Phase IIb trial as its primary clinical credential. Marketing materials that cite Phase IIa while omitting Phase IIb are misleading. The honest assessment: interesting pharmacology, clean safety data, non-monotonic dose-response that was never explained, and a pivotal trial that failed.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use